{"entity": "publication", "iuid": "99f62b09e0c146edba8556aaa8b73440", "timestamp": "2026-09-23T16:21:36.040Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/99f62b09e0c146edba8556aaa8b73440.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/99f62b09e0c146edba8556aaa8b73440"}}, "title": "A bispecific CD40 agonistic antibody allowing for antibody-peptide conjugate formation to enable cancer-specific peptide delivery, resulting in improved T proliferation and anti-tumor immunity in mice.", "authors": [{"family": "Mebrahtu", "given": "Aman", "initials": "A"}, {"family": "Laur\u00e9n", "given": "Ida", "initials": "I", "orcid": "0000-0003-0041-6084", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/6188000b91e54759af7c6789b7c4c63e.json"}}, {"family": "Veerman", "given": "Rosanne", "initials": "R"}, {"family": "Akpinar", "given": "G\u00f6zde G\u00fccl\u00fcler", "initials": "GG"}, {"family": "Lord", "given": "Martin", "initials": "M", "orcid": "0000-0002-3238-3187", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/9049f3f7eab747bf8bf4749e71cd0873.json"}}, {"family": "Kostakis", "given": "Alexandros", "initials": "A", "orcid": "0009-0006-2252-2645", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/3c3a0fe0badd4eac9fafc9497280e613.json"}}, {"family": "Astorga-Wells", "given": "Juan", "initials": "J", "orcid": "0000-0003-1017-8841", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/855ef6e5db6f4791a52eeae9ffb95a30.json"}}, {"family": "Dahllund", "given": "Leif", "initials": "L"}, {"family": "Olsson", "given": "Anders", "initials": "A"}, {"family": "Andersson", "given": "Oscar", "initials": "O"}, {"family": "Persson", "given": "Jonathan", "initials": "J"}, {"family": "Persson", "given": "Helena", "initials": "H"}, {"family": "D\u00f6nnes", "given": "Pierre", "initials": "P", "orcid": "0000-0002-4613-2952", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/307c54a242e24f77b06695e8b7e99ee8.json"}}, {"family": "Rockberg", "given": "Johan", "initials": "J"}, {"family": "Mangsbo", "given": "Sara", "initials": "S", "orcid": "0000-0002-1355-2678", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f4300802cdbd42b9843fe62bc6c96c33.json"}}], "type": "journal article", "published": "2024-11-05", "journal": {"title": "Nat Commun", "issn": "2041-1723", "volume": "15", "issue": "1", "pages": "9542", "issn-l": "2041-1723"}, "abstract": "Current antibody-based immunotherapy depends on tumor antigen shedding for proper T cell priming. Here we select a novel human CD40 agonistic drug candidate and generate a bispecific antibody, herein named BiA9*2_HF, that allows for rapid antibody-peptide conjugate formation. The format is designed to facilitate peptide antigen delivery to CD40 expressing cells combined with simultaneous CD40 agonistic activity. In vivo, the selected bispecific antibody BiA9*2_HF loaded with peptide cargos induces improved antigen-specific proliferation of CD8+ (10-15 fold) and CD4+ T cells (2-7 fold) over control in draining lymph nodes. In both virus-induced and neoantigen-based mouse tumor models, BiA9*2_HF demonstrates therapeutic efficacy and elevated safety profile, with complete tumor clearance, as well as measured abscopal impact on tumor growth. The BiA9*2_HF drug candidate can thus be utilized to tailor immunotherapeutics for cancer patients.", "doi": "10.1038/s41467-024-53839-5", "pmid": "39500897", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC11538452"}, {"db": "pii", "key": "10.1038/s41467-024-53839-5"}], "notes": [], "created": "2026-09-23T09:10:54.592Z", "modified": "2026-09-23T09:10:54.720Z"}